|Alchemy Pharmatech is an innovation-driven company developing drug delivery platforms in partnership with the pharmaceutical industry.
Focused on developing unique products to meet healthcare needs.
We are a well-funded company based on a leading innovation campus. Our portfolio includes products for generic medicines, vaccines, paediatrics, intensive care and animal health.
In line with our innovative focus we outsource non-core activities.
Aspiring to be global leaders in non-invasive intranasal delivery.
Robert Clayborough, (PhD, MBA) CEO: Over 17 years in Pharma in UK, EU & US. Held several senior management positions within inhalation & intranasal product development and commercialization.
Ian Harrison (MPhil, MBA, FRPharmS) CSO: Developer of the Naltos intranasal delivery system. A registered pharmacist who was Chief Pharmacist at Hammersmith Hospital and held a lectureship in clinical pharmacology. Experience in consultancy to the Pharma industry.
Michael Norris (FCMA) CFO: Non-exec CFO of 4 early stage medical device companies. 3 AIM flotations and over 20 public and private fundraisings ranging from £250k to £30m.
Penny Attridge Investment Advisor: A former research scientist and inventor of medical devices with specialist investment experience. Employed by Spark Impact, managers of the North West Fund for Biomedical.